We believe we have an important role and responsibility in improving access to medicines, vaccines and quality health care worldwide, helping to reduce the burden of disease in the parts of the world that need it most.
We work in collaboration with others—local communities, governments, donors, patient organizations, health care professionals, nongovernmental organizations (NGOs), multilateral organizations and others in the private sector—to contribute our expertise and knowledge.
The programs highlighted on this page are examples of our ongoing efforts. For descriptions of our completed programs, including the African Comprehensive HIV/AIDS Partnerships (ACHAP), the Alliance to Reduce Disparities in Diabetes, and the GARDASIL® Access Program, please click on the “Completed Programs” tab above.
Alliance to Advance Patient-Centered Cancer Care
In 2016, our company’s Foundation announced a new initiative, the Alliance to Advance Patient-Centered Cancer Care. The Alliance aims to increase timely access to patient-centered care and reduce disparities in cancer care, especially for vulnerable and underserved adult populations in the United States. Learn more.
Bridging the Gap: Reducing Disparities in Diabetes Care
With funding from our company’s Foundation, Bridging the Gap aims to improve access to high-quality diabetes care and reduce health disparities among vulnerable and underserved populations with type 2 diabetes in the United States. Learn more.
China-MSD HIV/AIDS Partnership
Our company’s Foundation committed $36 million to establish the China-MSD HIV/AIDS Partnership (C-MAP). C-MAP was the first large-scale public–private partnership between the Chinese government and a multinational company to focus on HIV/AIDS prevention and control. Learn more.
MCAN, established in 2005, a U.S.-based organization, was the only private foundation focused solely on addressing the complex and growing problem of childhood asthma within the United States. MCAN’s mission was to enhance the quality of life for children with asthma and their families, and to reduce the burden of the disease on them and on society. This program concluded in 2015. Learn more.
MECTIZAN® Donation Program
The MECTIZAN®(ivermectin) Donation Program is the longest-running disease-specific drug donation program and public–private partnership of its kind, and is widely regarded as one of the most successful public-private health collaborations in the world. Learn more.
Medical Outreach Program
Our company’s Medical Outreach Program was established in 1958. It is the primary mechanism through which our company donates its pharmaceuticals and vaccines for humanitarian assistance in the developing world and in support of disaster relief and emergency situations worldwide. Learn more.
MSD for Mothers
MSD for Mothers is a 10-year, $500 million initiative focused on creating a world where no woman dies giving life. Working together with committed partners, we believe we can help make pregnancy and childbirth a safe, healthy and joyful experience for women. Learn more.
U.S. Patient Assistance Programs
More than 55 years ago, our company created our first U.S. patient assistance program (PAP) to keep affordable medicines within patients’ reach. Today, our patient assistance offerings include several programs. Learn more.
The programs highlighted on this page are examples of our past programs and initiatives.
For details on these programs, please click on the links below.
African Comprehensive HIV/AIDS Partnerships
Together with our company’s Foundation and the Bill & Melinda Gates Foundation, we established the African Comprehensive HIV/AIDS Partnerships (ACHAP) in 2002 to support Botswana, a country disproportionately affected by HIV/AIDS. Learn more.
For lessons from ACHAP’s contributions to the fight against HIV/AIDS in Botswana, click here.
Alliance to Reduce Disparities in Diabetes
To address the growing problem of health care disparities related to type 2 diabetes in the U.S. among low-income and underserved adult populations, our company’s Foundation launched the Alliance to Reduce Disparities in Diabetes, with a commitment of $15 million. Learn more.
For a backgrounder on the Alliance to Reduce Disparities in Diabetes, click here. To see an infographic on how our Foundation is working with the Alliance to Reduce Disparities in Diabetes to bridge the gap in diabetes care, click here.
GARDASIL® Access Program
Through the GARDASIL® (Human Papillomavirus Quadrivalent [Types 6, 11, 16, 18] Vaccine, Recombinan) Access Program, we pledged to donate at least 3 million doses of GARDASIL for use in smaller-scale human papillomavirus (HPV) vaccination projects in eligible lowest-income countries around the world. Learn more.